AI Article Synopsis
- A meta-analysis was conducted to assess the effectiveness and safety of Sintilimab for cancer treatment, utilizing databases like CNKI, PubMed, and ScienceDirect to gather randomized controlled trials up to March 2022.
- Six randomized controlled trials with a total of 1,048 Sintilimab cases and 711 cases of other anticancer drugs were analyzed, revealing significant improvements in overall survival and progression-free survival for patients treated with Sintilimab.
- The results indicated that Sintilimab not only enhances clinical efficacy in cancer treatment but also has a lower rate of adverse reactions compared to other treatments, suggesting it may be a promising option for patients.
Article Abstract
Meta analysis was used to explore the efficacy and safety of Sintilimab in the treatment of cancer. The databases of CNKI, VIP, Wanfang Data, PubMed, ScienceDirect, the Cochrane Library and EMBASE were searched by computer to collect the randomized controlled trials published as of March 2022. The retrieval work was completed by two researchers alone. They screened the literature and extracted the data according to the nanodischarge standard, using Revman 5.4 software. The included studies were statistically analyzed. Six RCTs were included in this study, including 1,048 cases of Sintilimab and 711 cases of other anticancer drugs. Compared with the control group, the overall survival (HR = 1.64, 95% CI: 1.35-1.99, < 0.00001) and progression free survival (HR = 1.89, 95% CI: 1.59-2.25, < 0.00001) of cancer treated with Sintilimab were longer and more effective. Moreover, the risk ratio of any grade of adverse reactions (HR = 0.87, 95% CI: 0.74-1.03, = 0.11) and above grade III adverse reactions (HR = 0.84, 95% CI: 0.67-1.06, = 0.14) in the treatment of cancer with Sintilimab was lower and the safety was better. Compared with non-Sintilimab group, Sintilimab treatment can improve the clinical efficacy of tumor patients and has a lower incidence of adverse reactions. This treatment may be a promising treatment for cancer patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095967 | PMC |
| http://dx.doi.org/10.3389/fphar.2022.895187 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical, laboratory, and orbital imaging features of giant cell arteritis in comparison to non-arteritic anterior ischemic optic neuropath: a single center case series.
Front Ophthalmol (Lausanne)
December 2024
Department of Ophthalmology & Visual Sciences, School of Medicine, Washington University in St. Louis, St Louis, MO, United States.
Background: Giant cell arteritis (GCA) is the most common vasculitis in patients older than 50 years and is considered a "do not miss" diagnosis. However, it remains a diagnostic challenge given overlapping clinical syndromes such as non-arteritic anterior ischemic optic neuropathy (NAION) and poorly explored imaging findings.
Materials And Methods: In this retrospective study between the time period of January 2013 and December 2021, a total of 13 consecutive patients with a pathological diagnosis of GCA and 8 patients with clinical diagnosis of NAION were isolated.
The first case of alveolar echinococcosis from southern Croatia: progressive course of the disease in an immunocompromised patient.
Germs
September 2024
MD, PhD, Infectious Diseases Department, University Hospital of Split, HR-21000 Split, Croatia, and University of Split School of Medicine, HR-21000 Split, Croatia, and University Department of Health Studies of the University of Split, HR-21000 Split, Croatia.
Introduction: Alveolar echinococcosis is one of the most pathogenic zoonoses caused by the larval forms of . It is endemic in central Europe, but from 2001 to 2018, eight European countries reported their first cases of alveolar echinococcosis. These numbers testify to unprecedented spread of the infection.
View Article and Find Full Text PDFPrognostic value and immune landscapes of disulfidptosis‑related lncRNAs in bladder cancer.
Mol Clin Oncol
February 2025
Department of Urology Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Disulfidptosis, which was recently identified, has shown promise as a potential cancer treatment. Nonetheless, the precise role of long non-coding RNAs (lncRNAs) in this phenomenon is currently unclear. To elucidate their significance in bladder cancer (BLCA), a signature of disulfidptosis-related lncRNAs (DRlncRNAs) was developed and their potential prognostic significance was explored.
View Article and Find Full Text PDFCathelicidin, but not vitamin D, is associated independently with sepsis in pediatric patients with cancer and febrile neutropenia.
Mol Clin Oncol
February 2025
Clinical Pharmacology Laboratory, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Mexico City 09230, Mexico.
Sepsis and septic shock are major complications of febrile neutropenia (FN) in pediatric patients with cancer (PPCs). The aim of the present study was to determine the association of vitamin D (VD) and cathelicidin levels with sepsis and septic shock in PPCs with FN. A prospective cohort of PPCs with FN who had previously received cytotoxic chemotherapy was analyzed.
View Article and Find Full Text PDFEfficacy and safety of anlotinib combined with vinorelbine as second‑line treatment for elderly patients with advanced squamous cell lung carcinoma: A retrospective cohort.
Mol Clin Oncol
February 2025
Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, P.R. China.
The aim of the present study was to investigate the efficacy and safety of anlotinib combined with vinorelbine (NVB) as a second-line treatment for elderly patients with advanced squamous cell lung carcinoma (SqCLC). The present retrospective analysis included 48 elderly patients (aged ≥65 years) diagnosed with advanced SqCLC who received anlotinib in combination with NVB as a second-line therapy between January 2021 and December 2023. The primary endpoints assessed were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and safety profile.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!